AMINOPHYLLINE 250 MG10 ML

Страна: Израел

Език: английски

Източник: Ministry of Health

Активна съставка:

AMINOPHYLLINE

Предлага се от:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

АТС код:

R03DA05

Лекарствена форма:

SOLUTION FOR INJECTION

Композиция:

AMINOPHYLLINE 250 MG / 10 ML

Начин на приложение:

I.V

Вид предписание :

Required

Произведено от:

TEVA PHARMACEUTICAL WORKS PRIVATE LIMITED COMPANY, HUNGARY

Терапевтична група:

AMINOPHYLLINE

Терапевтична област:

AMINOPHYLLINE

Терапевтични показания:

For symptomatic relief or prevention of bronchial asthma and for treatment of reversible bronchospasm associated with chronic bronchitis and emphysema.

Дата Оторизация:

2014-05-31

Листовка

העדוה
העדוה
לע
לע
הרמחה
הרמחה
(
(
עדימ
עדימ
ןולעב )תוחיטב
ןולעב )תוחיטב
ל
ל
אפור
אפור
ןכדועמ(
ןכדועמ(
05.2013
05.2013
)
)
ךיראת
___________
MARCH 27, 2014
______
םש
רישכת
תילגנאב
רפסמו
םושירה
____________
AMINOPHYLLINE
INJECTION: 063 85 22594 21
_
םש
לעב
םושירה
_
עבט
תוישעת
תויטבצמרפ
.ד.ת ,מ"עב
3190
ת"פ ,
_
_
ספוט
הז
דעוימ
טורפל
תורמחהה
דבלב
!
תורמחהה
תושקובמה
קרפ
ןולעב
טסקט
יחכונ
טסקט
שדח
INDICATION
CONTRAINDICATIONS
POSOLOGY, DOSAGE &
ADMINISTRATION
SPECIAL WARNINGS AND
SPECIAL PRECAUTIONS FOR
USE
_Children_
Children have a marked sensitivity to the CNS
stimulant action of theophylline. This should be
taken into consideration for proper dosage
adjustment and monitoring.
Rapid
intravenous
injection
is
not
recommended in children.
_Use in the Elderly_
Elderly patients are at significantly greater risk
of
experiencing
serious
toxicity
from
theophylline than
younger
patients due
to
pharmacokinetic and pharmacodynamic changes
associated with aging.
Caution
should
be
exercised
when
aminophylline is administered to patients older
than 60 years of age. Theophylline clearance in
healthy adults older than 60 years of age is 30%
lower
than
healthy
younger
adults.
These
patients may require adjustment in dosage or
dosing interval
To reduce the undesirable stimulating effects of
aminophylline on the central nervous and cardiovascular
systems, intravenous administration of the drug should
be slow and should not exceed a rate of 25 mg/min.
Aminophylline has a narrow therapeutic index and
serum levels should be monitored regularly, particularly
during initiation of therapy.
Aminophylline injection should be administered
cautiously to patients over 55 years of age.
Elderly patients or those with cardiac or hepatic disease
should be monitored carefully for signs of theophylline
toxicity.
Care should be taken in patients unde

Данни за продукта

AMINOPHYLLINE 4. 5. 2014, RH
"
ע עבקנ הז ןולע טמרופ
"
רשואו קדבנ ונכותו תואירבה דרשמ י
."
רשואמ ןולע
:
יאמ
2014
“This leaflet form
at has been determined by the Ministry of Health and the content
thereof has
been checked and approved.” Date of approval: May 2014.
AMINOPHYLLINE
INJECTION
COMPOSITION
Each ampoule of 10 ml contains:
_Active Ingredient _
Aminophylline dihydrate
250 mg
_Other Ingredient _
Water for injection.
MECHANISM OF ACTION
Aminophylline is a soluble compound of theophylline with
ethylenediamine.
The main action of theophylline is a direct relaxation of the smooth
muscles of the
bronchial airways and pulmonary blood vessels, thus acting as a
bronchodilator.
It
has
also
been
demonstrated
that
aminophylline
has
a
potent
effect
on
diaphragmatic contractility in normal persons and may then be capable
of reducing
fatigability and therapy improve contractility in patients with
chronic obstructive airway
disease. The exact mode of action remains unsettled. Although
theophylline does
cause inhibition of phosphodiesterase with a resultant increase in
intracellular cyclic
AMP, other agents similarly inhibit the enzyme producing a rise of
cyclic AMP but are
unassociated with any demonstrable bronchodilation. Other mechanisms
proposed
include an effect on translocation of intracellular calcium,
prostaglandin antagonism,
stimulation
of
catecholamines
endogenously,
inhibition
of
cyclic
guanosine
monophosphate metabolism and adenosine receptor antagonisms. None of
these
mechanisms has been proved.
_In vitro_, theophylline has been shown to act synergistically with
beta agonists and
there is now available data which demonstrates an additive effect _ in
vivo_ with
combined use.
Theophylline also manifests other actions typical of the xanthine
derivatives such as
coronary vasodilation and diuresis.
INDICATIONS
For symptomatic relief or prevention of bronchial asthma and for
treatment of
reversible bronchospasm associated with chronic bronchitis and
emphyse